BR112018067454A2 - regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica - Google Patents
regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônicaInfo
- Publication number
- BR112018067454A2 BR112018067454A2 BR112018067454A BR112018067454A BR112018067454A2 BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2 BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- dosage regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
esta invenção refere-se a um novo regime de dosagem para administração de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida ou um derivado farmaceuticamente aceitável da mesma, a saber, no tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica (aecopd).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2016/050636 WO2017153702A1 (en) | 2016-03-08 | 2016-03-08 | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018067454A2 true BR112018067454A2 (pt) | 2019-01-15 |
Family
ID=55586330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018067454A BR112018067454A2 (pt) | 2016-03-08 | 2016-03-08 | regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica |
Country Status (9)
Country | Link |
---|---|
US (2) | US10603306B2 (pt) |
JP (1) | JP6741774B2 (pt) |
KR (1) | KR20180118667A (pt) |
AU (1) | AU2016397047B2 (pt) |
BR (1) | BR112018067454A2 (pt) |
CA (1) | CA3016488C (pt) |
MX (1) | MX2018010782A (pt) |
RU (1) | RU2713203C1 (pt) |
WO (1) | WO2017153702A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180118667A (ko) * | 2016-03-08 | 2018-10-31 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
GB201612238D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
AU2018382895B2 (en) | 2017-12-11 | 2024-05-16 | Mereo Biopharma 1 Limited | Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
DK3585383T3 (da) * | 2017-12-11 | 2021-04-19 | Mereo Biopharma 1 Ltd | Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i forebyggelsen af akutte forværringer af kronisk obstruktiv lungesygdom |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
CN1832928B (zh) | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
US20050277602A1 (en) | 2004-05-21 | 2005-12-15 | Grunstein Michael M | Methods employing agonists of P38 map kinase for the treatment of asthma |
CA2640665A1 (en) | 2006-02-10 | 2007-08-16 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
DK2827860T3 (en) * | 2012-03-20 | 2016-12-12 | Mereo Biopharma 1 Ltd | USE OF A pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
KR20180118667A (ko) * | 2016-03-08 | 2018-10-31 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
AU2016397046B2 (en) * | 2016-03-08 | 2022-05-12 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions |
-
2016
- 2016-03-08 KR KR1020187026084A patent/KR20180118667A/ko not_active IP Right Cessation
- 2016-03-08 WO PCT/GB2016/050636 patent/WO2017153702A1/en active Application Filing
- 2016-03-08 US US16/082,765 patent/US10603306B2/en active Active
- 2016-03-08 JP JP2018547431A patent/JP6741774B2/ja active Active
- 2016-03-08 RU RU2018132047A patent/RU2713203C1/ru active
- 2016-03-08 MX MX2018010782A patent/MX2018010782A/es unknown
- 2016-03-08 CA CA3016488A patent/CA3016488C/en active Active
- 2016-03-08 BR BR112018067454A patent/BR112018067454A2/pt not_active Application Discontinuation
- 2016-03-08 AU AU2016397047A patent/AU2016397047B2/en active Active
-
2020
- 2020-02-18 US US16/793,922 patent/US11129810B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20180118667A (ko) | 2018-10-31 |
JP6741774B2 (ja) | 2020-08-19 |
AU2016397047B2 (en) | 2022-04-07 |
CA3016488A1 (en) | 2017-09-14 |
WO2017153702A1 (en) | 2017-09-14 |
US10603306B2 (en) | 2020-03-31 |
US11129810B2 (en) | 2021-09-28 |
JP2019507786A (ja) | 2019-03-22 |
AU2016397047A1 (en) | 2018-09-06 |
CA3016488C (en) | 2023-04-11 |
RU2713203C1 (ru) | 2020-02-04 |
US20200281896A1 (en) | 2020-09-10 |
MX2018010782A (es) | 2019-01-10 |
US20190060279A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018067454A2 (pt) | regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
UY39706A (es) | Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue | |
CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
BR112017027843A2 (pt) | formulações farmacêuticas compreendendo tenofovir e emtricitabina | |
CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
PH12014502107B1 (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
AR096543A1 (es) | INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES | |
CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
AR100663A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
SV2016005313A (es) | Derivados de carboxamida | |
BR112018067784A2 (pt) | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias | |
CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
MX2016016491A (es) | Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas. | |
MY182008A (en) | Pharmaceutical formulations | |
MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
CY1122755T1 (el) | Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης | |
BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
EA201692013A1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида | |
AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
EA201692531A1 (ru) | Способы лечения инфекций |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |